Japan Tissue Engineering Co

Japan Tissue Engineering Co EBIT per osake

EBIT per osake yhtiöstä Japan Tissue Engineering Co (7774.T) 21.10.2026 päivämäärällä on −13,53 JPY. Edellisenä vuonna EBIT per osake oli −5,87 JPY — muutos 130,55 % (matalampi).

EBIT per osake

−13,53JPY

YoY

130,55%

Viimeksi päivitetty:

EBIT per osake yhtiöstä Japan Tissue Engineering Co on 2026 −13,53 JPY. EBIT per osake yhtiöstä Japan Tissue Engineering Co oli 2025 −5,87 JPY. Se laskee 130,55% matalampi edelliseen vuoteen verrattuna.

Japan Tissue Engineering Co EBIT per osake historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

EBIT per osake
Päivämäärä
EBIT per osake
1.1.2022
−12,27 JPY
1.1.2023
−17,93 JPY
1.1.2024
3,56 JPY
1.1.2025
−5,87 JPY
1.1.2026
−13,53 JPY
1.1.2027 (e)
35,32 JPY
1.1.2028 (e)
51,90 JPY
1.1.2029 (e)
62,66 JPY
Japan Tissue Engineering Co EBIT per osake historia
VUOSIEBIT per osakeYoY
est62,66JPY+20,73%
est51,90JPY+46,95%
est35,32JPY−361,03%
−13,53JPY+130,55%
−5,87JPY−264,92%
3,56JPY−119,85%
−17,93JPY+46,15%
−12,27JPY+6,71%
−11,50JPY+98,49%
−5,79JPY−32,51%
−8,58JPY−268,69%
5,09JPY−32,82%
7,57JPY−132,26%
−23,47JPY+3,93%
−22,59JPY−10,86%
−25,34JPY−15,94%
−30,14JPY−0,99%
−30,44JPY−2,84%
−31,33JPY+7,32%
−29,19JPY−46,36%
−54,42JPY+2,69%
−52,99JPY+121,18%
−23,96JPY—

Hae nämä tiedot Eulerpool API:n kautta

100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia

Japan Tissue Engineering Co Osakeanalyysi

Mitä Japan Tissue Engineering Co tekee? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Japan Tissue Engineering Co osakkeesta

Yhtiön Japan Tissue Engineering Co EBIT per osake on −13,53 JPY vuonna 2026.

EBIT per osake yhtiöstä Japan Tissue Engineering Co muuttui arvosta −5,87 JPY arvoon −13,53 JPY, mikä edustaa 130,55 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBIT per osake Japan Tissue Engineering Co:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBIT per osake mittaa operatiivisen voiton, joka on kohdistettu kullekin ulkona olevalle osakkeelle.

Hae nämä tiedot Eulerpool API:n kautta

100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia

Tuloslaskelma — Japan Tissue Engineering Co

Kaikki tunnusluvut — Japan Tissue Engineering Co